Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2
Copyright © 2023 Copyright: © 2023 Journal of Cancer Research and Therapeutics..
In December 2022, the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became dominant in China due to its high infectivity and lower mortality rate. The risk of critical illness and mortality among patients with hematologic malignancies who contracted SARS-CoV-2 was particularly high. The aim of this study was to draft a consensus to facilitate effective treatments for these patients based on the type and severity of the disease. Following the outbreak of the novel coronavirus in China, a steering committee consisting of experienced hematologists was formed by the Specialized Committee of Oncology and Microecology of the Chinese Anti-Cancer Association. The expert group drafted a consensus on the management and intervention measures for different types of hematologic malignancies based on the clinical characteristics of the Omicron variant of the SARS-CoV-2 infection, along with relevant guidelines and literature. The expert group drafted independent recommendations on several important aspects based on the epidemiology of the Omicron variant in China and the unique vulnerability of patients with hematologic malignancies. These included prophylactic vaccinations for those with hematologic malignancies, the use of plasma from blood donors who recovered from the novel coronavirus infection, the establishment of negative pressure wards, the use of steady-state mobilization of peripheral blood hematopoietic stem cells, the provision of psychological support for patients and medical staff, and a focus on maintaining a healthy intestinal microecology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Journal of cancer research and therapeutics - 19(2023), 6 vom: 01. Dez., Seite 1495-1500 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Jun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 03.01.2024 Date Revised 03.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4103/jcrt.JCRT_782_23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366475657 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366475657 | ||
| 003 | DE-627 | ||
| 005 | 20240108141327.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/jcrt.JCRT_782_23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1247.xml |
| 035 | |a (DE-627)NLM366475657 | ||
| 035 | |a (NLM)38156914 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Jun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2024 | ||
| 500 | |a Date Revised 03.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Copyright: © 2023 Journal of Cancer Research and Therapeutics. | ||
| 520 | |a In December 2022, the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became dominant in China due to its high infectivity and lower mortality rate. The risk of critical illness and mortality among patients with hematologic malignancies who contracted SARS-CoV-2 was particularly high. The aim of this study was to draft a consensus to facilitate effective treatments for these patients based on the type and severity of the disease. Following the outbreak of the novel coronavirus in China, a steering committee consisting of experienced hematologists was formed by the Specialized Committee of Oncology and Microecology of the Chinese Anti-Cancer Association. The expert group drafted a consensus on the management and intervention measures for different types of hematologic malignancies based on the clinical characteristics of the Omicron variant of the SARS-CoV-2 infection, along with relevant guidelines and literature. The expert group drafted independent recommendations on several important aspects based on the epidemiology of the Omicron variant in China and the unique vulnerability of patients with hematologic malignancies. These included prophylactic vaccinations for those with hematologic malignancies, the use of plasma from blood donors who recovered from the novel coronavirus infection, the establishment of negative pressure wards, the use of steady-state mobilization of peripheral blood hematopoietic stem cells, the provision of psychological support for patients and medical staff, and a focus on maintaining a healthy intestinal microecology | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Shao, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Qingming |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Baoli |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Qiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zelin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Liqiong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Danyu |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Zhijian |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Xiaohua |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Fuxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Jingye |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xiaojun |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Zhongjun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhiming |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Xiaoxing |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Zhiqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Wenyan |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhe |e verfasserin |4 aut | |
| 700 | 1 | |a Qiao, Mingqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Feifei |e verfasserin |4 aut | |
| 700 | 1 | |a Qi, Xiaofei |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Huijing |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Lijuan |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hongyan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hongyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xinyou |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jihao |e verfasserin |4 aut | |
| 700 | 1 | |a Chuanqing, T U |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Shu, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a He, Mingxin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Zhi |e verfasserin |4 aut | |
| 700 | 0 | |a Tumor and Microecology Committee of China Anti-Cancer Association |e verfasserin |4 aut | |
| 700 | 0 | |a Chinese Collaborative Group on Transformation of Infectious Immunology and Microecology Research |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cancer research and therapeutics |d 2005 |g 19(2023), 6 vom: 01. Dez., Seite 1495-1500 |w (DE-627)NLM174976801 |x 1998-4138 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:6 |g day:01 |g month:12 |g pages:1495-1500 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/jcrt.JCRT_782_23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 6 |b 01 |c 12 |h 1495-1500 | ||